Shoko Yokota

Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies

Takashi Kadowaki, Fuyuhiko Marubayashi, Shoko Yokota et al. · Expert Opinion on Pharmacotherapy · 2015 · 36 citations

Contributions of <scp><i>FASN</i></scp> and <scp><i>SCD</i></scp> gene polymorphisms on fatty acid composition in muscle from Japanese Black cattle

Shoko Yokota, Haruna Sugita, Astrid Ardiyanti et al. · Animal Genetics · 2012 · 32 citations

Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

Nobuya Inagaki, Maki Goda, Shoko Yokota et al. · Advances in Therapy · 2015 · 24 citations · Full text

Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

Takashi Kadowaki, Kazuoki Kondo, Noriyuki Sasaki et al. · Expert Opinion on Pharmacotherapy · 2017 · 24 citations

Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus:<i>post hoc</i>subgroup analyses according to body mass index in a 52-week open-label study

Nobuya Inagaki, Maki Goda, Shoko Yokota et al. · Expert Opinion on Pharmacotherapy · 2015 · 23 citations